Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals
Japan’s Asahi Kasei Pharma has stepped up with a deal to buy out Copenhagen-based Veloxis Pharmaceuticals for $1.3 billion, bagging an organ rejection drug in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
